Zobrazeno 1 - 10
of 478
pro vyhledávání: '"E Seregni"'
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
Autor:
F. Scalorbi, G. Argiroffi, M. Baccini, L. Gherardini, V. Fuoco, N. Prinzi, S. Pusceddu, E. M. Garanzini, G. Centonze, M. Kirienko, E. Seregni, M. Milione, M. Maccauro
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNETs patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered. Haematological, liver and renal toxiciti
Externí odkaz:
https://doaj.org/article/3380ac4098f3446e97f6596eaacd19af
Autor:
B. Frigerio, S. Morlino, E. Luison, E. Seregni, A. Lorenzoni, A. Satta, R. Valdagni, A. Bogni, C. Chiesa, M. Mira, S. Canevari, A. Alessi, M. Figini
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-8 (2019)
Abstract Background Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accu
Externí odkaz:
https://doaj.org/article/5ed00cef90f246bfae87335b9f35c781
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lisa Licitra, Francesca Platini, E Seregni, Stefano Cavalieri, Laura D. Locati, Salvatore Alfieri, Carlo Resteghini, Biagio Paolini, L Mazzeo, Cristiana Bergamini, Elena Colombo, A. Bottiglieri
Publikováno v:
Endocrine. 73:641-647
Radioactive-iodine (RAI)-resistant differentiated thyroid cancer (DTC) patients benefit from multi-kinase inhibitors (MKIs), such as lenvatinib. Incidence of treatment-related (TR) late toxicities has been not yet described. From January 2015 to June
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
Autor:
M. Kirienko, L. Gherardini, E Seregni, S Pusceddu, N Prinzi, G. Argiroffi, F. Scalorbi, Massimo Milione, M Maccauro, M. Baccini, Enrico Garanzini, V. Fuoco, Giovanni Centonze
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNETs patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered. Haematological, liver and renal toxicities were c
Autor:
P.B. Ruszniewski, J.R. Strosberg, M.E. Caplin, P.L. Kunz, L. Bodei, A. Hendifar, E. Mittra, E.M. Wolin, J.C. Yao, M.E. Pavel, E. Grande, E. van Cutsem, E. Seregni, H. Duarte, D. Niepel, A. Demange, E.P. Krenning
Publikováno v:
Médecine Nucléaire. 46:49-50
Autor:
A. Lorenzoni, C. Carniti, E. Seregni, G. Argiroffi, Annalisa Chiappella, Anna Guidetti, Alessandra Alessi, Anna Dodero, P. Verderio, s. Pizzamiglio, Paolo Corradini
Publikováno v:
Hematological Oncology. 39
Autor:
E Garagiola, LB Ferrario, O Bagni, CM Grana, S Lastoria, RE Pellerito, M Salgarello, E Seregni, S Severi, G Storto, A Versari, E Foglia
Publikováno v:
Value in Health. 25:S184
Autor:
S. Mazzaglia, C. Romanò, M.C. De Nile, M. Mira, C. Spreafico, M. Maccauro, V. Mazzaferro, A. Marchianò, E. Seregni, C. Chiesa
Publikováno v:
Physica Medica. 92:S92
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.